Your browser doesn't support javascript.
loading
Is a Simplified, Less Restrictive Low FODMAP Diet Possible? Results from a Double-Blind, Pilot Randomized Controlled Trial.
Singh, Prashant; Chey, Samuel W; Nee, Judy; Eswaran, Shanti; Lembo, Anthony; Chey, William D.
  • Singh P; Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan.
  • Chey SW; Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan.
  • Nee J; Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Eswaran S; Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan.
  • Lembo A; Digestive Disease Institute, Division of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio.
  • Chey WD; Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan. Electronic address: wchey@med.umich.edu.
Article en En | MEDLINE | ID: mdl-38729393
ABSTRACT
A low fermentable oligo-, mono-, di-saccharides, and polyols (FODMAPs) diet (LFD) is the most evidence-based dietary therapy for patients with irritable bowel syndrome (IBS).1 However, the current step-down approach to the LFD has significant limitations including being costly, complex, time-consuming, and associated with reduced dietary intake of some micronutrients.2-4 Recently, a step-up approach has been proposed that restricts only a limited number of FODMAPs initially, evaluating symptom response and restricting additional FODMAPs only if necessary.2,5,6 In a double-blind trial, fructans and galacto-oligosaccharides were found to be the most likely FODMAP subgroups to trigger IBS symptoms.7 To date, no study has compared the efficacy of a traditional LFD restriction phase with a more targeted or simplified restriction phase. In a double-blind, pilot-feasibility randomized controlled trial, we compared the efficacy of a 4-week FODMAP-simple restriction phase (eliminating solely fructans and galactooligosaccharides) and a traditional LFD restriction phase in patients with IBS with diarrhea (IBS-D) (ClinicalTrials.gov registration number NCT05831306).

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article